Gyre Therapeutics, Inc.
GYRE
$8.68
-$2.53-22.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 100.64M | 105.76M | 105.03M | 111.59M | 115.69M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 100.64M | 105.76M | 105.03M | 111.59M | 115.69M |
| Cost of Revenue | 3.80M | 3.88M | 3.96M | 4.18M | 4.49M |
| Gross Profit | 96.84M | 101.87M | 101.08M | 107.40M | 111.20M |
| SG&A Expenses | 73.48M | 73.62M | 77.82M | 75.38M | 77.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 90.21M | 89.53M | 94.66M | 92.68M | 95.07M |
| Operating Income | 10.43M | 16.23M | 10.38M | 18.91M | 20.62M |
| Income Before Tax | 15.37M | 23.22M | -77.83M | -70.57M | -70.76M |
| Income Tax Expenses | 3.68M | 5.32M | 5.82M | 8.42M | 9.01M |
| Earnings from Continuing Operations | 11.70 | 17.90 | -83.65 | -78.99 | -79.76 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -4.45M | -5.81M | -5.17M | -6.98M | -7.88M |
| Net Income | 7.25M | 12.09M | -88.82M | -85.97M | -87.65M |
| EBIT | 10.43M | 16.23M | 10.38M | 18.91M | 20.62M |
| EBITDA | 12.13M | 17.81M | 11.79M | 20.07M | 21.86M |
| EPS Basic | 0.08 | 0.14 | -1.25 | -1.20 | -1.21 |
| Normalized Basic EPS | 0.06 | 0.10 | -0.03 | 0.02 | 0.02 |
| EPS Diluted | 0.02 | 0.05 | -1.34 | -1.30 | -1.29 |
| Normalized Diluted EPS | 0.05 | 0.08 | -0.05 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 343.52M | 340.36M | 326.97M | 304.92M | 283.00M |
| Average Diluted Shares Outstanding | 394.89M | 395.51M | 382.12M | 358.39M | 332.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |